Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group

Antimicrob Agents Chemother. 2000 Nov;44(11):3155-7. doi: 10.1128/AAC.44.11.3155-3157.2000.


We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase III
  • Randomized Controlled Trial

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Delavirdine / therapeutic use*
  • Double-Blind Method
  • Drug Resistance, Microbial
  • Drug Therapy, Combination
  • HIV Infections / drug therapy*
  • HIV Reverse Transcriptase / genetics
  • HIV-1 / drug effects
  • HIV-1 / genetics
  • Humans
  • Treatment Outcome
  • Zidovudine / therapeutic use


  • Anti-HIV Agents
  • Zidovudine
  • Delavirdine
  • HIV Reverse Transcriptase